{"id":31223,"date":"2019-02-12T12:00:00","date_gmt":"2019-02-12T12:00:00","guid":{"rendered":"https:\/\/www.euforea.org\/news\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\/"},"modified":"2019-02-12T12:00:00","modified_gmt":"2019-02-12T12:00:00","slug":"fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma","status":"publish","type":"news","link":"https:\/\/www.euforea.org\/de\/news\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\/","title":{"rendered":"Fazit zu den Herausforderungen bei der Einf\u00fchrung von Biologika bei Patienten mit CRSwNP und Asthma"},"content":{"rendered":"<div class=\"paragraph paragraph--text-columns paragraph-id--1481 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<h2>Rhinology Future Debates Br\u00fcssel 2018<\/h2>\n<p>In diesem kurzen Video teilt Prof. Dr. Claus Bachert seine Gedanken zu Therapie und monoklonalen Antik\u00f6rpern.<\/p>\n<h3>Podiumsteilnehmende<\/h3>\n<p>Catherine Lucet, Claus Bachert, Joaquim Mullol, Peter Hellings, Charles Pilette, Renaud Louis, Philippe Rombaux, Patientenvertreter.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"paragraph paragraph--text-columns paragraph-id--1482 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<div class=\"video-container\"><center><iframe title=\"YouTube-Videoplayer\" src=\"https:\/\/www.youtube.com\/embed\/ItSpdFhs_cA?rel=0\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/center><\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Rhinology Future Debates Br\u00fcssel 2018 In diesem kurzen Video teilt Prof. Dr. Claus Bachert seine Gedanken zu Therapie und monoklonalen Antik\u00f6rpern. Podiumsteilnehmende Catherine Lucet, Claus Bachert, Joaquim Mullol, Peter Hellings, Charles Pilette, Renaud Louis, Philippe Rombaux, Patientenvertreter.<\/p>\n","protected":false},"author":1,"featured_media":31240,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[182],"tags":[187,157,158,160,162,183,184,185,186],"class_list":["post-31223","news","type-news","status-publish","has-post-thumbnail","hentry","category-rhinology-future-debates","tag-asthma","tag-chronische-rhinosinusitis-crs","tag-patienten","tag-crswnp","tag-gesundheitsfachkrafte","tag-rhinologie","tag-debatten","tag-rhinology-future-debates","tag-biologika"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.3 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fazit zu den Herausforderungen bei der Einf\u00fchrung von Biologika bei Patienten mit CRSwNP und Asthma - EUFOREA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.euforea.org\/de\/news\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fazit zu den Herausforderungen bei der Einf\u00fchrung von Biologika bei Patienten mit CRSwNP und Asthma\" \/>\n<meta property=\"og:description\" content=\"Rhinology Future Debates Br\u00fcssel 2018 In diesem kurzen Video teilt Prof. Dr. Claus Bachert seine Gedanken zu Therapie und monoklonalen Antik\u00f6rpern. Podiumsteilnehmende Catherine Lucet, Claus Bachert, Joaquim Mullol, Peter Hellings, Charles Pilette, Renaud Louis, Philippe Rombaux, Patientenvertreter.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.euforea.org\/de\/news\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\/\" \/>\n<meta property=\"og:site_name\" content=\"EUFOREA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/euforea\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@euforea\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\\\/\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\\\/\",\"name\":\"Fazit zu den Herausforderungen bei der Einf\u00fchrung von Biologika bei Patienten mit CRSwNP und Asthma - EUFOREA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Rhinology20Future20Debates202018_22.png\",\"datePublished\":\"2019-02-12T12:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\\\/#breadcrumb\"},\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Rhinology20Future20Debates202018_22.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Rhinology20Future20Debates202018_22.png\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/waehlen-sie-ihren-weg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Fazit zu den Herausforderungen bei der Einf\u00fchrung von Biologika bei Patienten mit CRSwNP und Asthma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/\",\"name\":\"EUFOREA\",\"description\":\"Inspiring the Future of Respiratory Care\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#organization\",\"name\":\"EUFOREA\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"width\":500,\"height\":500,\"caption\":\"EUFOREA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/euforea\\\/\",\"https:\\\/\\\/x.com\\\/euforea\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/euforea\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/EUFOREA\",\"https:\\\/\\\/www.instagram.com\\\/euforeaofficial\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fazit zu den Herausforderungen bei der Einf\u00fchrung von Biologika bei Patienten mit CRSwNP und Asthma - EUFOREA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.euforea.org\/de\/news\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\/","og_locale":"de_DE","og_type":"article","og_title":"Fazit zu den Herausforderungen bei der Einf\u00fchrung von Biologika bei Patienten mit CRSwNP und Asthma","og_description":"Rhinology Future Debates Br\u00fcssel 2018 In diesem kurzen Video teilt Prof. Dr. Claus Bachert seine Gedanken zu Therapie und monoklonalen Antik\u00f6rpern. Podiumsteilnehmende Catherine Lucet, Claus Bachert, Joaquim Mullol, Peter Hellings, Charles Pilette, Renaud Louis, Philippe Rombaux, Patientenvertreter.","og_url":"https:\/\/www.euforea.org\/de\/news\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\/","og_site_name":"EUFOREA","article_publisher":"https:\/\/www.facebook.com\/euforea\/","twitter_card":"summary_large_image","twitter_site":"@euforea","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.euforea.org\/de\/news\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\/","url":"https:\/\/www.euforea.org\/de\/news\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\/","name":"Fazit zu den Herausforderungen bei der Einf\u00fchrung von Biologika bei Patienten mit CRSwNP und Asthma - EUFOREA","isPartOf":{"@id":"https:\/\/www.euforea.org\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.euforea.org\/de\/news\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\/#primaryimage"},"image":{"@id":"https:\/\/www.euforea.org\/de\/news\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Rhinology20Future20Debates202018_22.png","datePublished":"2019-02-12T12:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.euforea.org\/de\/news\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\/#breadcrumb"},"inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.euforea.org\/de\/news\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\/"]}]},{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.euforea.org\/de\/news\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\/#primaryimage","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Rhinology20Future20Debates202018_22.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Rhinology20Future20Debates202018_22.png","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/www.euforea.org\/de\/news\/fazit-zu-den-herausforderungen-bei-der-einfuehrung-von-biologika-bei-patienten-mit-crswnp-und-asthma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.euforea.org\/de\/waehlen-sie-ihren-weg\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.euforea.org\/de\/news\/"},{"@type":"ListItem","position":3,"name":"Fazit zu den Herausforderungen bei der Einf\u00fchrung von Biologika bei Patienten mit CRSwNP und Asthma"}]},{"@type":"WebSite","@id":"https:\/\/www.euforea.org\/de\/#website","url":"https:\/\/www.euforea.org\/de\/","name":"EUFOREA","description":"Inspiring the Future of Respiratory Care","publisher":{"@id":"https:\/\/www.euforea.org\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.euforea.org\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de-DE"},{"@type":"Organization","@id":"https:\/\/www.euforea.org\/de\/#organization","name":"EUFOREA","url":"https:\/\/www.euforea.org\/de\/","logo":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.euforea.org\/de\/#\/schema\/logo\/image\/","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","width":500,"height":500,"caption":"EUFOREA"},"image":{"@id":"https:\/\/www.euforea.org\/de\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/euforea\/","https:\/\/x.com\/euforea","https:\/\/www.linkedin.com\/company\/euforea","https:\/\/www.youtube.com\/c\/EUFOREA","https:\/\/www.instagram.com\/euforeaofficial\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/news\/31223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/comments?post=31223"}],"version-history":[{"count":0,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/news\/31223\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/media\/31240"}],"wp:attachment":[{"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/media?parent=31223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/categories?post=31223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/tags?post=31223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}